NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球膠原病市場(2021-2027)

Global Collagen Vascular Diseases Market 2021-2027

出版商 Orion Market Research Pvt Ltd 商品編碼 1025411
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
全球膠原病市場(2021-2027) Global Collagen Vascular Diseases Market 2021-2027
出版日期: 2021年07月13日內容資訊: 英文
簡介

在預測期內,全球膠原病市場預計將以約 7.5% 的顯著複合年增長率增長。膠原蛋白疾病的患病率上升是市場擴張的主要因素。膠原蛋白疾病是關節疼痛和腫脹等疾病的主要原因,並且通過增加治療需求來推動市場增長。此外,諸如治療這些疾病的持續藥物發現以及政府和非政府組織的努力等醫學進步正在進一步推動市場增長。此外,新興國家的機會不斷擴大,例如先進醫療基礎設施的發展,預計將推動市場增長。

在 COVID-19 危機期間,全球膠原病市場出現下滑,因為患者住院率大幅下降,並且在 COVID-19 期間僅提供緊急醫療和初級保健服務。因此,診斷測試的數量正在減少,這影響了用於治療膠原病的藥物的銷售。

全球膠原病市場根據疾病類型、診斷、治療和最終用戶進行分類。根據疾病類型,市場分為狼瘡、類風濕性關節炎和硬皮病。此外,根據診斷,市場分為總血細胞計數、紅細胞沉降率(ESR)、CRP、風濕因子等(顯微尿液分析、血清肌酐),根據治療劑,市場是皮質類固醇。它分為類固醇、免疫抑製劑、內絲蛋白受體拮抗劑和其他(鈣通道阻滯劑、PDE-5 抑製劑、螯合劑)。此外,根據最終用戶,它分為醫院/診所、診斷中心和研究機構。預計在預測期內,類風濕性關節炎將佔據疾病類型的很大一部分。類風濕性關節炎的主要原因是吸煙和缺乏運動等久坐生活方式的增加,這會導致肥胖並在該領域獲得市場份額。

本報告調查了全球膠原病市場,提供了市場概況,分析了市場增長和障礙、市場機會、疾病類型/診斷/治療/最終用戶/區域市場規模。它提供了趨勢等系統信息和預測、競爭條件和主要公司的概況。

目錄

第 1 章報告概述

第 2 章市場概覽和洞察

  • 調查範圍
  • 分析師洞察和當前市場趨勢
  • 規則

第 3 章競爭形勢

  • 主要公司分析
    • 概述
    • 財務分析
    • SWOT 分析
  • 重要的戰略分析
  • Covid 對主要參與者的影響

第 4 章市場決定因素

  • 增長因素
  • 抑制因素
  • 市場機會

第 5 章市場細分

  • 按疾病類型
    • 自身免疫性膠原病
    • 遺傳性膠原病
  • 按診斷
    • 全血細胞計數
    • 紅細胞沉降率 (ESR)
    • C-反應蛋白
    • 類風濕因子
    • 其他(抗核抗體、顯微尿液分析和血清肌酐)
  • 按治療藥物
    • 皮質類固醇
    • 免疫抑製劑
    • 內皮素受體拮抗劑
    • 其他(鈣通道阻滯劑、PDE-5 抑製劑和螯合劑)
  • 最終用戶
    • 醫院和診所
    • 診斷中心
    • 研究機構

第 6 章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他領域

第 7 章公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG`
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Co.
  • Cadila Pharmaceuticals Ltd
  • Corbus Pharmaceuticals Holdings, Inc.
  • Cytori Therapeutics Inc.
  • Danaher Corp.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GenWay Biotech Inc.
  • ImmuPharma PLC
  • Pfizer Inc.
  • Sanofi SA
  • Siemens Healthcare AG
  • Thermo Fisher Scientific, Inc.
  • Svar Life Science AB
  • MorphoSys AG
  • Merck & Co., Inc.
目錄
Product Code: OMR2023840

Full-title:Global Collagen Vascular Diseases Market Size, Share & Trends Analysis Report by Disease Type (Autoimmune Collagen Vascular Diseases and Hereditary Collagen Vascular Diseases), By Diagnostics (Complete Blood Count, Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein, Rheumatoid Factor, and Others (Urinalysis with Microscopic Analysis & Serum Creatinine)), By Therapeutics (Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Antagonists, and Others (Calcium Channel Blockers, PDE-5 Inhibitors & Chelating Agents)), and By End-Users (Hospital & Clinics, Diagnostic Centers, Research Institutes) Forecast, 2021-2027.

The global market for Collagen Vascular Diseases is projected to have a considerable CAGR of around 7.5% during the forecast period. The rise in the prevalence of collagen vascular diseases has been the primary driver of market expansion. It has been the leading cause of disability, aching, causing pain, and swelling, in the joints and increasing the need for treatment, thereby promoting the market growth. Furthermore, medical advancements that include ongoing drug discovery and government and non-government organizational initiatives to treat these diseases are further driving the market growth. Additionally, evolving opportunities in emerging economies such as the development of advanced healthcare infrastructure facilities are also expected to propel the growth of the market.

The global collagen vascular diseases market suffered a downfall during the COVID-19 crisis as the number of patient hospitalizations has decreased significantly, and only emergency and primary care services are available during COVID-19. Therefore, this has reduced the diagnostic tests and impacted the sales of therapeutics for collagen vascular diseases.

The global collagen vascular diseases market is segmented based on disease type, diagnostics, therapeutics, and end-users. Based on the disease type, the market is classified into lupus, rheumatoid arthritis, scleroderma. Further, based on diagnostics, the market is segregated into complete blood count, erythrocyte sedimentation rate (ESR), c-reactive protein, rheumatoid factor, and others (Urinalysis with Microscopic Analysis & Serum Creatinine), based on therapeutics, the market is classified into corticosteroids, immunosuppressive agents, endothelin receptor antagonists and others (Calcium Channel Blockers, PDE-5 Inhibitors & Chelating Agents). Furthermore, based on end-user, the market is segmented into hospitals & clinics, diagnostic centres, research institutes. During the forecast period, rheumatoid arthritis is expected to have a significant share among the disease's types. The main causes of rheumatoid arthritis are the increase in the adoption of sedentary lifestyles among people, including smoking and physical inactivity, which leads to obesity therefore this is increasing the segment share in the market.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is anticipated to witness a significant share in the global collagen vascular diseases market due to increasing healthcare spending and increased population awareness about the diagnosis and treatment of these collagen vascular diseases. Furthermore, specialized drug discovery for these diseases in the region also drives the market growth in the North American market. Whereas, Asia-Pacific is expected to be the fastest-growing region in the global collagen vascular diseases market. The attributable factors are improving healthcare infrastructure and rising medical tourism in the region. Moreover, the increasing adoption of urban lifestyles among the population, combined with favourable regulatory policies for biosimilars, will fuel the growth of therapeutics for collagen vascular diseases in the Asia Pacific region. The key players of the market include AbbVie Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., Pfizer Inc, Beckman Coulter, Inc., and Bayer AG, among others.

Research Methodology

The market study of the global Collagen Vascular Diseases market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Collagen Vascular Diseases Market Research and Analysis by Disease Type
  • Global Collagen Vascular Diseases Market Research and Analysis by Diagnostics
  • Global Collagen Vascular Diseases Market Research and Analysis by Therapeutics
  • Global Collagen Vascular Diseases Market Research and Analysis by End-user

The Report Covers

  • Comprehensive research methodology of the global Collagen Vascular Diseases market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Collagen Vascular Diseases market.
  • Insights about market determinants that are stimulating the global Collagen Vascular Diseases market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Collagen Vascular Diseases Industry
  • Recovery Scenario of Global Collagen Vascular Diseases Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Competitive Landscape

  • 3.1. key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key strategy analysis
  • 3.3. Impact of Covid on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Collagen Vascular Diseases Market by Disease Type
    • 5.1.1. Autoimmune Collagen Vascular Diseases
      • 5.1.1.1. Lupus
      • 5.1.1.2. Rheumatoid Arthritis
      • 5.1.1.3. Scleroderma
    • 5.1.2. Hereditary Collagen Vascular Diseases
  • 5.2. Global Collagen Vascular Diseases Market by Diagnostics
    • 5.2.1. Complete Blood Count
    • 5.2.2. Erythrocyte Sedimentation Rate (ESR)
    • 5.2.3. C-Reactive Protein
    • 5.2.4. Rheumatoid Factor
    • 5.2.5. Others (Antinuclear Antibodies, Urinalysis with Microscopic Analysis & Serum Creatinine)
  • 5.3. Global Collagen Vascular Diseases Market by Therapeutics
    • 5.3.1. Corticosteroids
    • 5.3.2. Immunosuppressive Agents
    • 5.3.3. Endothelin Receptor Antagonists
    • 5.3.4. Others (Calcium Channel Blockers, PDE-5 Inhibitors & Chelating Agents)
  • 5.4. Global Collagen Vascular Diseases Market by End-Users
    • 5.4.1. Hospital & Clinics
    • 5.4.2. Diagnostic Centers
    • 5.4.3. Research Institutes

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie Inc.
  • 7.2. Amgen Inc.
  • 7.3. Bayer AG`
  • 7.4. Bio-Rad Laboratories, Inc.
  • 7.5. Bristol-Myers Squibb Co.
  • 7.6. Cadila Pharmaceuticals Ltd
  • 7.7. Corbus Pharmaceuticals Holdings, Inc.
  • 7.8. Cytori Therapeutics Inc.
  • 7.9. Danaher Corp.
  • 7.10. Eli Lilly and Co.
  • 7.11. F. Hoffmann-La Roche Ltd.
  • 7.12. GenWay Biotech Inc.
  • 7.13. ImmuPharma PLC
  • 7.14. Pfizer Inc.
  • 7.15. Sanofi SA
  • 7.16. Siemens Healthcare AG
  • 7.17. Thermo Fisher Scientific, Inc.
  • 7.18. Svar Life Science AB
  • 7.19. MorphoSys AG
  • 7.20. Merck & Co., Inc.

LIST OF TABLES

  • 1. GLOBAL COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
  • 2. GLOBAL AUTOIMMUNE COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
  • 3. GLOBAL LUPUS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL RHEUMATOID ARTHRITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL SCLERODERMA MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL HEREDITARY COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2020-2027 ($ MILLION)
  • 8. GLOBAL COMPLETE BLOOD COUNT MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 9. GLOBAL ERYTHROCYTE SEDIMENTATION RATE (ESR) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL C-REACTIVE PROTEIN MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL RHEUMATOID FACTOR MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL COLLAGEN VASCULAR DISEASES FOR OTHERS (URINALYSIS WITH MICROSCOPIC ANALYSIS & SERUM CREATININE) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2020-2027 ($ MILLION)
  • 14. GLOBAL CORTICOSTEROIDS MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 15. GLOBAL IMMUNOSUPPRESSIVE AGENTS MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 16. GLOBAL ENDOTHELIN RECEPTOR ANTAGONISTS MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 17. GLOBAL COLLAGEN VASCULAR DISEASES FOR OTHERS (CALCIUM CHANNEL BLOCKERS, PDE-5 INHIBITORS & CHELATING AGENTS) MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 18. GLOBAL COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
  • 19. GLOBAL COLLAGEN VASCULAR DISEASES FOR HOSPITAL & CLINICS MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 20. GLOBAL COLLAGEN VASCULAR DISEASES FOR DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 21. GLOBAL COLLAGEN VASCULAR DISEASES FOR RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 22. GLOBAL COLLAGEN VASCULAR DISEASESMARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 23. NORTH AMERICAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 24. NORTH AMERICAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
  • 25. NORTH AMERICAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2020-2027 ($ MILLION)
  • 26. NORTH AMERICAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2020-2027 ($ MILLION)
  • 27. NORTH AMERICAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
  • 28. EUROPEAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 29. EUROPEAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
  • 30. EUROPEAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2020-2027 ($ MILLION)
  • 31. EUROPEAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2020-2027 ($ MILLION)
  • 32. EUROPEAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
  • 33. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 34. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
  • 35. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2020-2027 ($ MILLION)
  • 36. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2020-2027 ($ MILLION)
  • 37. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
  • 38. REST OF THE WORLD COLLAGEN VASCULAR DISEASES MARKE TRESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 39. REST OF THE WORLD COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
  • 40. REST OF THE WORLD COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2020-2027 ($ MILLION)
  • 41. REST OF THE WORLD COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2020-2027 ($ MILLION)
  • 42. REST OF THE WORLD COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL COLLAGEN VASCULAR DISEASESMARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL COLLAGEN VASCULAR DISEASESMARKET BY SEGMENT, 2020-2027 (% MILLION)

  • 3. RECOVERY OF GLOBAL COLLAGEN VASCULAR DISEASESMARKET, 2020-2027 (%)
  • 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SHARE BY DISEASE TYPE, 2020 VS 2027 (%)
  • 5. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SHARE BY DIAGNOSTICS, 2020 VS 2027 (%)
  • 6. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SHARE BY THERAPEUTICS , 2020 VS 2027 (%)
  • 7. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SHARE BY END-USERS, 2020 VS 2027 (%)
  • 8. GLOBAL COLLAGEN VASCULAR DISEASES MARKETSHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL AUTOIMMUNE COLLAGEN VASCULAR DISEASES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL LUPUS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBAL RHEUMATOID ARTHRITIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. GLOBAL SCLERODERMA MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 13. GLOBAL HEREDITARY COLLAGEN VASCULAR DISEASES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 14. GLOBAL COMPLETE BLOOD COUNT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 15. GLOBAL ERYTHROCYTE SEDIMENTATION RATE (ESR) MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 16. GLOBAL C-REACTIVE PROTEIN MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 17. GLOBAL RHEUMATOID FACTOR MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 18. GLOBAL COLLAGEN VASCULAR DISEASES FOR OTHERS (URINALYSIS WITH MICROSCOPIC ANALYSIS & SERUM CREATININE) MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 19. GLOBAL CORTICOSTEROIDS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 20. GLOBAL IMMUNOSUPPRESSIVE AGENTS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 21. GLOBAL ENDOTHELIN RECEPTOR ANTAGONISTS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 22. GLOBAL COLLAGEN VASCULAR DISEASES FOR OTHERS (CALCIUM CHANNEL BLOCKERS, PDE-5 INHIBITORS & CHELATING AGENTS) MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 23. GLOBAL HOSPITAL & CLINICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 24. GLOBAL DIAGNOSTIC CENTERS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 25. GLOBAL RESEARCH INSTITUTES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 26. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 27. US COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 28. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 29. UK COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 30. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 31. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 32. ITALY COLLAGEN VASCULAR DISEASES MARKETSIZE, 2020-2027($ MILLION)
  • 33. SPAIN COLLAGEN VASCULAR DISEASES MARKETSIZE, 2020-2027($ MILLION)
  • 34. REST OF EUROPE COLLAGEN VASCULAR DISEASES MARKETSIZE, 2020-2027($ MILLION)
  • 35. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 36. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 37. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 38. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 39. REST OF ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 40. REST OF THE WORLD COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)